Glycosylation of (+)--viniferin was investigated using glucosyltransferase from Phytolacca americana (PaGT3) as a biocatalyst. (+)-ε-Viniferin was converted by PaGT3 into its 4b-and 13b--D-glucosides, the inhibitory activities on histamine release from rat peritoneal mast cells of which were higher than that of (+)--viniferin.
Vitis heyeana is a traditional drug used for the treatment of arthritis, fever, carbuncles, and inflammatory conditions [1] . Vitis species have been reported to produce bioactive oligostilbenes [1] . (+)--Viniferin is an important component of oligostilbenes from V. heyeana. Use of (+)--viniferin as a medicine is limited because of its low water-solubility and poor absorption after oral administration. Glycosylation by biocatalysts such as plant cultured cells and plant glycosyltransferases is a useful method to prepare water-soluble glycoside derivatives from lipophilic compounds. One-step glycosylation by biocatalysts is more convenient than chemical glycosylation, which requires tedious steps such as protection and deprotection of the hydroxyl groups of the sugar moieties. Glycosylation occurs readily in plant cells, i.e., many kinds of secondary metabolites such as saponins and anthocyanins are produced in the form of glycosides in higher plants. Many of these secondary metabolites have specific physiological activities and have been widely used in folk medicines [2] . Therefore, the glycosylation of organic compounds by biocatalysts is of pharmaceutical importance and has been carried out for many exogenous compounds [2] [3] [4] [5] [6] [7] [8] . Although studies on physiological properties of (+)--viniferin have been reported [1] , there are few reports on glycosylation of (+)--viniferin by biocatalysts. Herein, we report, for the first time, the glycosylation of (+)--viniferin by glucosyltransferase from Phytolacca americana.
The glucosyltransferase from P. americana (PaGT3) [9, 10] was expressed in Escherichia coli. PaGT3, purified using a His-accept column, was used as a biocatalyst. Substrate, (+)--viniferin (1, 50 M), and UDP-glucose (100 M) were administered to a conical flask containing 5 M PaGT3 and 50 mM potassium phosphate buffer (pH 7.2, 5 mL), and the flask was incubated at 35°C for 1 day on a rotary shaker. After the incubation period, the reaction was stopped by adding 1.5% trifluoroacetic acid to the flask. Compounds 2 and 3 were isolated from the extracts of the reaction mixture with n-BuOH. The chemical structures of the products were determined on the basis of their FABMS, 1 identified as -viniferin 4b--D-glucoside (2) and -viniferin 13b--D-glucoside (3) ( Figure 1 ).
The FABMS of product 2 showed a pseudomolecular ion [M+Na] + peak at m/z 639 consistent with a molecular formula of C 34 H 32 O 11 (calcd. 639 for C 34 H 32 O 11 Na), suggesting that a hexose was introduced to the substrate. The 1 H NMR spectrum of 2 displayed an anomeric proton signal at  5.00 (1H, d, J=7.6 Hz). The sugar component in product 2 was determined to be -D-glucopyranose, according to the chemical shifts of the sugar carbon signals. The 13 C NMR spectrum of 2 showed an anomeric carbon resonance at  99.2. The HMBC spectrum of 2 exhibited an interaction between the anomeric proton at the 1'-position ( 5.00) and the carbon at 4bposition ( 158.2). This finding established that the glucopyranosyl residue was attached to the phenolic hydroxyl group at C-4b of (+)--viniferin (1). Thus, the structure of compound 2 was determined to be -viniferin 4b-O--D-glucopyranoside. NMR spectrum of compound 3 showed a signal for an anomeric protons at  4.90 (1H, d, J=8.0 Hz), suggesting the presence of a anomer. The 13 C NMR spectrum of 3 included an anomeric carbon signal at  99.5. On the basis of the chemical shifts of the carbon signals due to the sugar moiety, the sugar component of 3 was determined as -D-glucopyranose. HMBC correlation between the proton signal at  4.90 (H-1') and the carbon signal at  159.7 (C-13b) established that the glucosyl residue was attached at the 13bposition of (+)--viniferin (1). Thus, compound 3 was identified as -viniferin 13b-O--D-glucopyranoside.
The inhibitory effects of compounds 1-3 on histamine release from rat peritoneal mast cells were examined. As a result, -viniferin 13b-O--D-glucopyranoside (3) showed the highest inhibitory activity (22% inhibition). The inhibitory activity of -viniferin 4b-O--D-glucopyranoside (2) (20% inhibition) was higher than that of (+)--viniferin (1) (12% inhibition), suggesting that glycosylation of (+)--viniferin (1) improved its inhibitory activity on histamine release from rat peritoneal mast cells.
Thus, it was demonstrated that glucosyltransferase from P. americana (PaGT3) can glycosylate (+)--viniferin to its 4b-and 13b--D-glucosides, the inhibitory activities on histamine release from rat peritoneal mast cells of which were higher than that of (+)--viniferin. The present method is useful for the practical preparation of a water-soluble derivative of (+)--viniferin and is environmentally friendly. Further study on the pharmacological properties of glycosides of (+)--viniferin is now in progress in our laboratory.
Experimental
General: HPLC was carried out with a column, Crest Pak C18S Expression and purification of PaGT3: Expression and purification of PaGT3 were performed as described previously [9, 10] . PaGT3 cDNA were cloned into pQE30, and the resulting plasmids were transformed into E. coli M15 cells. The transformants were grown in LB medium with continuous shaking at 30°C. The harvested cells were resuspended in buffer A (15 mM potassium phosphate, 1 mM EDTA, 2 mM 2-mercaptoethanol). Cells were lysed by sonication, and cellular debris was removed by centrifugation. The supernatant was applied to a His-accept column equilibrated with buffer A. The column was washed with buffer A to remove impurities, and the bound PaGT enzyme was eluted with buffer A supplemented with 200 mM imidazole. The purified enzyme solution was dialyzed with 50 mM Tris-HCl (pH 7.2) containing 5 mM dithiothreitol, and stored at -80°C.
Glycosylation procedure: Glucosylation reactions were performed at 35°C for 24 h in 5 mL of 50 mM potassium phosphate buffer (pH 7.2) supplemented with 50 μM substrate, 100 μM UDP-glucose, and 5 μM enzyme. The incubation was stopped by adding 1.5% trifluoroacetic acid; the reaction mixture was analyzed by HPLC. The reaction mixture was extracted with n-BuOH. The n-BuOH fraction was concentrated by evaporation and the residue was dissolved in water. The water fraction was applied to Diaion HP20, washed with water, and eluted with methanol. The methanol solution was analyzed by HPLC.
Inhibition of histamine release from rat peritoneal mast cells:
The inhibitory effects of ε-viniferin and its glycosides on compound 48/80-induced histamine release from rat peritoneal mast cells were examined as follows. Peritoneal mast cells were collected from the abdominal cavities of rats (Male Wistar rats, Nippon SLC) and purified to a level higher than 95%. The purified mast cells were suspended in a physiological buffered solution (PBS) containing 145 mM NaCl, 2.7 mM KCl, 1.0 mM CaCl 2 , 5.6 mM glucose, and 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (pH 7.4) to give approximately 10 4 mast cells/mL. Cell viability was always greater than 90% as judged by the trypan blue exclusion test. Mast cells were preincubated with the test compound (1 µM) for 15 min at 37°C, and subsequently exposed to compound 48/80 at 0.35 μg/mL. Histamine release was determined by a fluorometric assay and was expressed as a percentage of total histamine.
